The stock's fall snapped a four-day winning streak.

This was the stock's fourth consecutive day of gains.

The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $430.00 to $433.00 in a research note released on Friday morning,Benzinga reports. The brokerage ...

The drug offers a non-addictive alternative to opioids, marking 'an important public health milestone in acute pain ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) gapped up prior to trading on Friday after Scotiabank raised their price target on the stock from $430.00 to $433.00. The stock had ...

An effort two decades in the making, Vertex Pharmaceuticals Inc.’s suzetrigine gained U.S. FDA approval as the first drug targeting the NaV1.8 pain signal. Branded Journavx, the oral small molecule is ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...